Here, use of a low, vascular-normalizing dose of anti-VEGFR2 antibody led to increased tumor infiltration of CD4+ and CD8+ T cells and improved the efficacy of a cancer vaccine therapy in a CD8+ T cell-dependent manner in mouse breast cancer models [47]. This evidence concerns the gene CD8A and neoplasm.